

Lockington, Elliott (SPAC/PSPC)

From: Jeevan Singh <jeevan@numed.io>
Sent: July 15, 2020 3:58 PM
To: Alain Dorion
Subject: RE: Remdesivir (Generic)

haha no worries.

Remdesivir developed by Gilead is a Covid-19 treatment drug that has shown to reduce mortality rates by 62% and reduces hospital stays. You can read their data presentation here: <https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19>

USA has bought the global supply from Gilead for the next 4 months and possible extension. The way its going Gilead supply is going to be locked for a year between USA, Japan and some European countries. Gilead is allowing manufacturers to make generic versions where it can't meet supply. Most of those suppliers are in India and we can't get a pencil out of India if it writes covid data. Bangladesh is different due to the world trade organization exception for least developed countries.

Canada is currently conducting an expedited review process on the drug. However, if we want to get access then we most likely need a deal in principle done prior to approvals.

Hope this helps

cheers

J

On July 15, 2020 at 3:30 PM Alain Dorion <Alain.Dorion@tpsgc-pwgsc.gc.ca> wrote:

Maybe a stupid question but what is Remdesivir?

From: Jeevan Singh [mailto:jeevan@numed.io]
Sent: July 15, 2020 3:18 PM
To: Alain Dorion <Alain.Dorion@tpsgc-pwgsc.gc.ca>
Cc: BD BD <bd@numed.io>
Subject: Remdesivir (Generic)

ATTENTION

This email originated from outside of the Government of Canada. Do not click links or open attachments unless you recognize the sender and believe the content is safe. For more information regarding reporting suspicious emails, please visit the [Information Technology Security Directorate](#) on MySource.

Ce courriel provient de l'extérieur du Gouvernement du Canada. Ne cliquez pas sur les liens et n'ouvrez pas les pièces jointes, à moins de connaître l'expéditeur et croire que le contenu est sécuritaire. Pour de plus amples renseignements sur la façon de signaler les courriels suspects, veuillez consulter la page [Sécurité en technologie de l'information](#) sur maSource.

Hi Alain,

I was in touch with the minister's office, they told me that they are interested in remdesivir and I should coordinate with you.

We have access to the generic version of the drug from Beximco Pharma under the LDC trade exception granted by WTO to Bangladesh pharma companies. Beximco manufacturing facilities are Health Canada approved. We are engaging with Beximco directly but should that approach fail, we will bring in Biocare, a Philippines based company that has a tie-up Beximco to market that drug. Should that fail, then we have other options as well.

In a nutshell, we will need some support from you in terms of buying volume so we can be put in a better position to lock up that supply. We would also need some ongoing support on an as-needed basis. I am also coordinating with Health Canada re. approval process.

I am looping in Vikas, he is the current country head (Germany) for Alkem a multi-billion dollar pharma company. He will be doing me a personal favor and guiding me throughout the entire procurement process.

The supplies are obviously very limited as global cases keep mounting so we need to act proactively and fast. Please let me know what you think and how we can best approach this.

Best Regards,

Jeevan Singh

Email: Jeevan@numed.io

Direct: +1 (613) 8944819



PS: I'll put together the gloves proposal shortly. Already sent the manufacturer a note.

This email is confidential and is intended for the exclusive use of the addressee. Any other person is strictly prohibited from disclosing, distributing or reproducing it. If you have received this email by mistake please notify the sender and delete all copies.